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Renal transplantation (RT) is the best option for patients with end-stage renal disease, but the half-life is limited to a decade due to
progressive deterioration of renal function and transplant failure from chronic allograft nephropathy (CAN), which is the leading
cause of transplant loss. Extensive research has been done to understand the pathogenesis, the biological pathways of fibrogenesis,
and potential therapeutic targets for the prevention and treatment of CAN. Despite the advancements in the immunosuppressive
agents and patient care, CAN continues to remain an unresolved problem in renal transplantation. The aim of this paper is to
undertake a comprehensive review of the literature on the pathogenesis, biological pathways of RT fibrogenesis, and potential
therapeutic targets for the prevention and therapy of CAN.
1. Introduction
Renal transplantation (RT) is the best form of treatment
for end-stage renal disease (ESRD), because this improves
the quality of life and patient survival and is cost-effective
[1]. Chronic allograft nephropathy (CAN) is the leading
cause of late RT loss; hence, attention has been focussed
on understanding the pathogenesis of RT fibrogenesis and
interventional strategies to prevent and treat CAN [2].
CAN is characterised by a relatively slow but variable
rate of decline in renal function after first 3 months of
RT, often in combination with proteinuria and hypertension
[3]. CAN should be differentiated from other causes of
transplant dysfunction such as rejection (acute, subclinical,
and chronic), calcineurin inhibitor (CNI) nephrotoxicity,
glomerulonephritis (recurrent and de novo), nephrosclerosis
(secondary to old donor age, recipient hypertension, hyper-
lipidaemia, and smoking), and others (ureteric obstruction,
BK virus nephropathy, and transplant renal artery stenosis)
[4, 5].
Schweitzer et al. from Minnesota in 1991 reported, in a
cohort of 2396 patients over a period of 20 years (1970–1989),
chronic rejection as the leading cause of graft loss following
RT amounting to 24%, followed by death with functioning
graft (18%), infection (13%), and acute rejection (11%) [6].
More lately, Sijpkens et al. from Netherlands reported that
54 of the 654 (8%) RTs performed between 1983 and 1997
had histological evidence of CAN and CAN accounted for
37% of graft loss after first 6 months post-RT [7]. Naesens
et al. have reported that the global burden of early chronic
histological damage within the first year after transplantation
significantly affected the long-term survival of the allografts
[8]. Currently, chronic antibody-mediated rejection from
both anti-human leucocyte antigen (HLA) antibodies and
non-HLA antibodies is being recognised as an important
cause of CAN [9, 10].
The aim of this review is to consolidate the published
evidence on the pathogenesis, biological pathways of RT
fibrogenesis, and potential therapeutic targets for the preven-
tion and therapy of CAN.
2. Literature Search Strategy
The literature search was carried out in PubMed and relevant
websites using the words “renal transplantation,” “chronic
allograft nephropathy,” “chronic rejection,” “graft loss,” “trans-
plant fibrosis,” and “prevention,” Relevant references were
compiled in the EndNote software (X6.0.1; Bld 6599).
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Table 1: Risk factors implicated in CAN.
Immunological risk factors Nonimmunological risk factors
Histocompatibility
Acute rejection episodes
Suboptimal
immunosuppression
Subclinical rejections
Anti-donor antibodies
Noncompliance
Ischaemia-reperfusion injury
Brain death
Infection (cytomegalovirus and BK
virus)
CNI toxicity
Donor factors: age, hypertension,
smoking, diabetes, gender, and
reduced renal mass
Recipient factors: race, hypertension,
smoking, diabetes, and
hyperlipidaemia
3. Risk Factors Implicated in CAN
Both antigen-dependent (immunological) and antigen-
independent (nonimmunological) factors are implicated in
the aetiology of CAN (Table 1). On occasions, it is difficult
to pinpoint a single aetiological factor, as more than one
factor is usually implicated in the pathogenesis of CAN [11].
Recurrent episodes of acute tubular-interstitial rejection
can explain the interstitial fibrosis and tubular atrophy
observed in some cases. Cytokines released during episodes
of rejection, including interleukin-1, fibroblast growth factor,
and platelet derived growth factor, are likely to play a role in
promoting the fibroblast and smooth muscle proliferation
seen in allograft vessels. In cases with prior documented
intimal arteritis, vessel thickening can be explained as a direct
result of immunologic vascular injury. Graft atherosclerosis
leads to ischaemic glomerulopathy [12].
Once glomerulosclerosis has developed, the remaining
glomeruli undergo compensatory hypertrophy, increased
glomerular capillary hydraulic pressure, and increased glom-
erular filtration. These haemodynamic forces damage the
glomerular capillary endothelium, cause mesangial expan-
sion, and accentuate the evolution of chronic transplant
glomerulopathy [12]. In support of this hypothesis, it has been
shown experimentally that if the increase in glomerular filtra-
tion rate is prevented by putting animals on a severely protein
restricted diet, the rate of progression of glomerular sclerosis
in allograft kidneys is retarded [13, 14]. Arteriolosclerosis
and interstitial fibrosis in the allograft may also occur as a
result of hypertension, recurrent pyelonephritis, and chronic
cyclosporine or tacrolimus toxicity. The relative contribution
of these various processes to the ultimate loss of any given
allograft may be difficult to determine by pathological evalu-
ation alone. The aetiologically noncommittal term “chronic
allograft nephropathy” was in fact coined to accommodate
this difficulty [15].
4. Pathology of CAN
The kidney affected by CAN looks pale and fibrotic with a
dense, thickened, adherent capsule. Under light microscopy,
characteristic changes are found in the glomerular, tubule-
interstitial, and microvascular compartments (Figure 1).
4.1. Microvascular Changes. The “transplant arteriopathy”
characterised by severe intimal proliferation and luminal
narrowing associated with sparse infiltration of T-cells and
macrophages is seen in all arteries extending from main
renal artery to the interlobar arteries. The intima shows
concentric fibrous thickening with intact internal elastic lam-
ina. The matrix appears pale in haematoxylin eosin-stained
sections and contains acid mucopolysaccharides, collagen,
and increased hyaluronic acid.The cells in the intima include
𝛼-smooth actin-positive myofibroblasts and smooth muscle
cells. The media generally shows no abnormality. Arterioles
do not show intimal changes.Hyalinosis of arteries is a feature
of CNI toxicity, never seen in animalmodels not onCNI drug
treatment [16].
4.2. Glomerular Changes. In CAN, ischaemic glomeruli,
atubular glomeruli, and chronic transplant glomerulopathy
are the histological findings. Morphometric analysis of CAN
shows populations of small (ischaemic) and large (hyperfil-
trating) glomeruli.The ischaemic glomeruli are characterised
by wrinkling and collapse of glomerular capillary wall asso-
ciated with extracapillary fibrotic material [17].
Chronic transplant glomerulopathy (CTG) comprises
a spectrum of histological abnormalities which include
thickening or duplication of glomerular capillary basement
membrane (double contour lesion) andmesangial expansion.
CTG implies chronic endothelial injury of glomerular cap-
illary loops and is clinically accompanied by substantial or
nephrotic range proteinuria, renal function impairment, and
reduced RT survival [18].
4.3. Tubulointerstitial Changes. As a result of ischaemia
caused by microvascular changes described above, the
tubules undergo atrophy, which may also result from tubuli-
tis. The tubular basement membranes (TBM) are thickened
and duplicated, but some show pronounced shrinkage and
thinning of TBM and thereby dilatation. The interstitium
shows fibrosis with variablemononuclear infiltrate with small
lymphocytes, plasma cells, and mast cells. The fibrosis can
have different patterns, such as dense and focal, diffuse
and fine, striped, or subcapsular. The peritubular capillaries
(PTC) are depleted leaving behind only traces of original
basement membrane as seen on silver- or PAS-stained sec-
tions [19].
4.4. Electron Microscopy. Under electron microscopy, the
CTG is associated with deposition of flocculent or fibril-
lary material; mesangial cellular proliferation with matrix
expansion; multilamination or multilayering of the capillary
basement membrane. Multilamination of capillary basement
membrane as high as seven or more layers indicates past
or recent endothelial injury with subsequent repair, which
was present in 38% of failed transplants ascribed to CAN
(Figure 2) [20].
5. Theories of Pathogenesis of CAN
CAN represents the summated effects of tissue injury result-
ing from several pathogenic insults and the healing response
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Figure 1: Haematoxylin and eosin (H & E) stain showing (a) tubular atrophy, interstitial fibrosis (→ ), (b) glomerulosclerosis (→ ), and (c)
concentric obliterative arteriolopathy (→ ); (d) Masson’s trichrome stain showing interstitial fibrosis (→ ); (e) silver stain (→ ); and (f) PAS
stain showing double contour of glomerular capillary basement membrane (→ ) (magnification ×20) (source: Northern General Hospital,
Sheffield).
of the kidney to injury, in addition to the influence of
alloimmunity and immunosuppression. Various hypotheses
have been proposed to explain the pathogenesis of CAN,
which include (1) chronic rejection, (2) input-stress model,
(3) cumulative damage, (4) oxidative stress, (5) cytokine
excess, (6) epithelial-mesenchymal transition (EMT) induced
fibrosis, (7) replicative senescence, (8) insertion/deletion
polymorphism of angiotensin-converting enzyme, and (9)
acetylcholine excess [21–30].
6. Biological Pathways in Allograft Fibrosis
Majority of extracellular matrix (ECM) in the kidney is com-
posed of collagens I, III, V, VII, and XV and fibronectin. The
structural framework is formed by proteoglycans, polysac-
charides, and glycoproteins. The tubular basement mem-
brane consists of collagen IV and laminin. Fibrosis or scarring
is the overgrowth and sclerosis of the tissues due to the
excessive deposition of ECM, which becomes pathological
when the functioning architecture is destroyed, leading to
functional impairment [31].
The pathway of progression of fibrosis in RT kidney lead-
ing to RT loss comprises time-dependent series of patholog-
ical insults causing histological changes. There are two broad
phases of RT damage observed in sequential biopsy studies,
starting with early tubulointerstitial injury [32] followed
by later microvascular and glomerular abnormalities and
further progressive interstitial fibrosis and tubular atrophy
[23].
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Figure 2: Electron microscopy showing (a) a normal glomerulus (E: endothelial cell; P: podocytes; Lumen: capillary lumen); and (b)
transplant glomerulopathy with presence of a well-developed basement membrane (BM) along the entire capillary circumference, mesangial
expansion (M), and accumulation of subendothelial deposit (D) (magnification ×7000) (source: Northern General Hospital, Sheffield).
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Figure 3: Showing pathways of fibrosis in chronic allograft nephropathy.
Figure 3 summarises the events leading fibrosis to CAN
and can be arbitrarily divided into three phases, namely,
the initiation phase, the fibrogenesis phase, and the matrix
accumulation phase. In the initiation phase, tissue injury is
caused by antigen-dependent of antigen-independent factors.
Regardless of the nature of initiating agent, fibrogenesis
phase sets in, which consists of inflammatory and prolif-
erative responses regulated by chemokines, cytokines and
growth factors. The cascade of events results in the matrix
accumulation phase due to either increased production
and/or decreased degradation of matrix, culminating in
fibrosis [33].
Injury to the vascular endothelium, glomerular, or tubu-
lar epithelium caused by antigen-dependent (immunolog-
ical) or antigen-independent pathways (toxic, ischaemic,
or mechanical) leads to the secretion of proinflammatory
mediators (lipid mediators, chemokines, cytokines, adhesion
molecules, and growth factors) by all intrinsic renal cells.
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Expression of adhesion molecules and chemokines by the
endothelial cells of the glomerular and peritubular capillaries
supports leucocyte arrest and transmigration either into the
mesangium or the interstitial space. The infiltration and
proliferation of leucocytes enhances the local production
of cytokines and chemokines. Furthermore, the neutrophils
and macrophages generate reactive oxygen species and lipid
mediators contributing to local tissue damage and glomerular
and tubulointerstitial inflammation, which results in haema-
turia, leukocyturia, and proteinuria [34, 35].
Macrophages themselves secrete ECM components, but
they are alsomajor source of growth factors such as fibroblast
growth factor (FGF), transforming growth factor-𝛽 (TGF-
𝛽), tumour necrosis factor-𝛼 (TNF-𝛼), epithelial growth
factor (EGF), and platelet-derived growth factor (PDGF).The
TGF-𝛽 superfamily includes three TGF-𝛽 isoforms (TGF-𝛽1,
TGF-𝛽-2, and TGF-𝛽-3), activins, and bone morphogenetic
proteins (BMPs) [36]. Both antigen-dependent and inde-
pendent injuries lead to the expression of TGF-𝛽 isoforms,
which act by engaging intracellular signalling cascades of
canonical SMAD or noncanonical, non-SMAD family of
proteins. The SMAD pathways are activated/phosphorylated
by TGF-𝛽1 receptors such as activins-receptor like kinase
(ALK) 5 and ALK1. However, TGF-𝛽 also activates the non-
canonical, SMAD-independent pathways such as Ras/rho
and MAPK, NF-kB, or PI3kinase/AKT pathway. Receptor-
activated SMAD protein complexes translocate within the
nucleus and initiate transcription of target genes [37–39].
TGF-𝛽1 is the key modulator of glomerulosclerosis,
tubulointerstitial fibrosis, and EMT in the kidney. TGF-
𝛽1 sets off a cascade of profibrotic molecules through the
activation of SMAD2/3 [40] and MEK signalling pathways
[41], which results in the transcription of genes and activation
of molecules involved in matrix deposition and fibrosis.
Proinflammatory and profibrotic cytokines stimulate the
proliferation ofmesangial cells in the glomerulus and of inter-
stitial fibroblasts in the interstitium, which, upon activation,
increase the synthesis of extracellular matrix components.
Leucocyte infiltration, fibroblast proliferation, and matrix
deposition as well as oedema increase the interstitial volume.
There is proliferation of resident fibroblasts and of the myofi-
broblasts derived from tubular epithelial cells by a process
of EMT, induced by the macrophage-derived, profibrotic
cytokine FGF-2 [42]. In the glomeruli, stimulated mesangial
cells secrete the collagen type IV, laminin, andfibronectin that
contribute to glomerulosclerosis [43]. Mesangial expansion
leads to narrowing, obliteration, or dilatation of glomerular
capillaries. This results in damage to podocytes and down-
stream peritubular capillaries leading to destruction of entire
nephrons [44].
The tubulointerstitial compartment shows progressive
expansion of ECM through continuous stimulation of fibrob-
lasts. Transdifferentiation of activated tubular epithelial cells
leads ECM expansion. Massive increase in interstitial volume
from infiltrates and expansion of ECM leads to an increase
in the distance between the peritubular capillaries and the
tubules, thereby impairing oxygen diffusion as well as tubular
reabsorption and excretory function [45]. The tubulointer-
stitial ischaemia is considered to be an important factor for
tubular cell apoptosis, necrosis, and tubular atrophy [46].
Finally, extensive loss of transplant renal parenchyma leads
to transplant failure. At a late stage of CAN, although the
leucocytic infiltration resolves, renal fibroblasts maintain the
synthesis of ECM due to sustained hypoxia and autocrine
stimulation [47]. Myofibroblasts contribute to the contrac-
tion of the fibrous tissue with scarring leading to a shrunken
transplant kidney at the terminal stage.
7. Potential Targets for Prevention
and Therapy of CAN
The modulation of fibrosis is central in RT. As CAN is the
end result of injury caused by acute rejection, infection,
ischaemia reperfusion injury, alloantibody-mediated rejec-
tion, and drug toxicity, each factor needs to be prevented
and treated appropriately. Shortening of cold ischaemia
time, HLA-matching and reduced sensitisation, avoidance
of CNI-toxicity, cytomegalovirus prophylaxis, and treatment
of subclinical rejection detected through protocol biopsies
are paramount [48]. Early detection of changes of CAN
by microarray mRNA assays, which detect alteration in the
transcriptomes at a very early stage of interstitial fibrosis, even
before infiltration by inflammatory cells, has opened up a
new avenue for interventions at this stage [35, 49]. At the
molecular level, targeting the blockade of synthesis or action
of enzymes, cytokines, chemokines, and growth factors at
various stages of renal fibrogenesis is being investigated, both
in experimental and clinical settings, which are discussed
below.
7.1. Chemokine Blockade. Blockade of chemokines (BX471:
CCR1 antagonist; and met-RANTES: RANTES antagonist)
is proven to be effective in preventing RT fibrosis in rat
transplant models. No parallel study has been carried out in
human RTs [50, 51]. Chemokines are a family of small size
(8–10 kDa) chemotactic cytokines, which, in transplantation,
induce recruitment and activation of T cells and monocytes
or macrophages. So far more than 50 chemokines and
20 chemokine receptors have been identified. Members of
chemokines family are divided into four groups (C, CC,
CXC, and CX
3
C) based upon the position of their first two
cysteine residues. They are further classified as inflammatory
or haemostatic.
In Fisher-to-Lewis rat allografts, BX-471, chemokine
receptor type 1 (CCR1) antagonist, prevented the infiltration
of T cells andmacrophages, decreased cell proliferation (ED1,
CD8, and Ki67), and reduced expression of acute phase
reactive proinflammatory genes (HO-1, osteopontin) and
molecules associated with fibrosis (PAI-1, TGF-𝛽, and bigly-
can).There was a significantly lower number of SMA-positive
interstitial myofibroblasts and reduction in the deposition of
collagen [51].
Similarly, Met-RANTES, a chemokines receptor antag-
onist (CCR5), in Fisher-to-Lewis allografts, blocked the
effects of RANTES (regulated on activation, normal T-
cell expressed) reducing the infiltration of lymphocytes and
macrophages in allografts, accompanied by decreasedmRNA
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expression of interleukin (IL)-2, IL-1 beta, tumour necrosis
factor-alpha (TNF-alpha), and RANTES and thereby reduced
glomerulosclerosis, tubulointerstitial fibrosis, and protein-
uria [50].
7.2. Blockade of Oxidative Stress. In human RT, intraoper-
ativeadministration of recombinant human superoxide dis-
mutase decreased the incidence of acute and chronic rejec-
tion [52], whereas treatment pre- and postreperfusion made
no difference in allograft function 48 hours after transplant
[53]. Further clinical trials are needed to determine the type,
dose, and timing of antioxidant intervention.
7.3. Renin-Angiotensin System Blockade. Angiotensin II acti-
vates TGF-𝛽1, apoptosis, oxidative stress, and atherogenesis
in the cardiovascular system and the kidney [54–56]. Renin-
angiotensin system (RAS) blockade has antifibrotic and
antiproteinuric properties in experimental and clinical stud-
ies of kidney diseases. Angiotensin II, acting via aldosterone,
increases plasminogen activator inhibitor-1 (PAI-1) and limits
plasmin production from plasminogen, resulting matrix
overproduction. Angiotensin-converting enzyme inhibitors
(ACE-I) and angiotensin (Ang) II receptor blockade lead to
reduced intragraft expression of TGF-𝛽 and reduced protein-
uria. Therefore, this has now become the first line therapy in
patients with CKD and hypertension or proteinuria [57].
A large retrospective study of over 2000 RT recipients
showed that 10-year patient and graft survival was signifi-
cantly improved in individuals treated with ACE-I or Ang
II receptor blockers [58]. A meta-analysis of 21 randomised
controlled trials including 1549 patients showed that RAS
blockade was associated with significant drop in haematocrit
(−3.5%), GFR (−5.8%), and proteinuria (−0.47 g/d) during
a 2-year time period, but there are insufficient data to
determine the effect on patient or graft survival [59].
In comparison with patients with native kidney disease,
there is little information from prospective randomised
controlled trials examining the effects of RAS blockade on
long-term outcomes in RT. The ongoing Canadian ACE-I
trial (ISR-78129473) and American Angiotensin II Blockade
for the prevention of cortical interstitial expansion and graft
loss in RT recipients (NCT00067990) studies will provide
clinically meaningful evidence on the effect of RAS blockade
on patient and graft survival in RT recipients [59, 60].
7.4. Inhibition of TGF-𝛽1. TGF-𝛽1 is upregulated in animal
and human allografts undergoing chronic rejection and in
chronic cyclosporine-induced tubulointerstitial fibrosis [61,
62]. On the other hand, TGF-𝛽1 exerts immunosuppressive
effects in the RT and helps the generation of T-regulatory
cells thereby inducing certain degree of graft tolerance,
which is beneficial to the graft. Therefore, caution needs
to be exercised in blockade of TGF-𝛽1. For example, TGF-
𝛽1 knockout mice die at an early stage from uncontrolled
multifocal inflammatory disease and evidence suggests that
overexpression of TGF-𝛽1 in early acute rejection may pre-
vent chronic rejection and improved outcomes [63, 64];
hence, TGF-𝛽1 may be a less than optimal target in transplant
settings. Alternatively, downstream targetsmay be more use-
ful approach. To date, no clinical trial has been undertaken
on the use of TGF-𝛽1 in human RT. Agents, used to inhibit
TGF-𝛽1, are described below.
7.4.1. Pirfenidone. Pirfenidone (PFD) (5-methyl-a-phenyl-2-
(1H)-pyridone) is an orally active synthetic agent that inhibits
expression of TGF-𝛽1, epidermal growth factor, PDGF, and
fibroblast proliferation [65]. In a rat model of cyclosporine
nephrotoxicity, PFD reduced TGF-𝛽 mRNA protein expres-
sion and fibrosis by 50% and reduced proapoptotic gene
expression [65, 66]. Administration of PFD in focal segmen-
tal glomerulosclerosis led to 25% improvement in the rate of
decline of kidney function [67]. PFD has not been tested in
human clinical transplantation yet.
7.4.2. Relaxin. Relaxin is a peptide hormone, a member of
insulin growth factor (IGF) family, and a naturally occurring
inhibitor of collagen deposition during normal development,
aging, and pregnancy. In cultured human renal fibroblasts,
exposure to relaxin inhibited TGF-𝛽-induced type I collagen
and fibronectin synthesis and signalling via SMAD2 and
also stimulated matrix metalloproteinase (MMP)-2 and -
9 secretion [68]. Furthermore, in a relaxin gene-knockout
mouse, the progressive renal fibrosis and deteriorating renal
function were reversed with recombinant relaxin [69]. In
a bromoethylamine-induced model of renal fibrosis in the
rat, relaxin administration was associated with a signifi-
cant decrease in interstitial fibrosis at the corticomedullary
junction, accompanied by a decrease in the number of
ED-1 positive cells (an index of macrophage infiltration)
and in the intensity of immunohistochemical staining for
transforming growth factor-beta [70]. However, there have
been no preclinical studies in transplantation.
7.4.3. Decorin. Decorin is a small leucine rich proteoglycan
that forms complexes with TGF-𝛽 leading to inhibition
or sequestration within the ECM. In experimental models
of obstructive uropathy, treatment with decorin reduced
proteinuria, collagen deposition, and expression of TGF-𝛽
within the kidney [71, 72].
7.4.4. Endothelin-1 Inhibition. Endothelin-1 (ET-1) is a vaso-
active peptide with potent vasoconstrictive properties, which
is produced in tubular epithelium, macrophages, and fibrob-
lasts. ET-1 also promotes fibrogenesis by upregulating TGF-
𝛽, directly stimulates collagen synthesis, and limits collagen
degradation [73]. The use of nonselective ET-1 receptor
blockade in an ischaemic injury rat model limited the fall in
GFR [74]. Bosentan, a nonselective ET antagonist, has been
used in a rat tracheal allograft model where it ameliorated
bronchiolitis obliterans, but the experience of ET-1 receptor
blockade in clinical transplantation is limited [75].
7.4.5. Bone Morphogenetic Protein-7 (BMP-7). BMP-7 is a
member of the TGF𝛽-1 family, which signals through the
ALK3 and ALK6 type I receptors to phosphorylate SMAD1,
SMAD5, and SMAD8, whereas TGF𝛽1 signals through the
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ALK5 type 1 receptor to phosphorylate SMAD2 and SMAD3
[76]. BMP-7 can counterbalance the profibrotic effects of
TGF𝛽-1 by the activation of regulatory SMAD1, SMAD5, and
SMAD8. It was observed that renal allografts with tubuloin-
terstitial fibrosis and EMT were associated with upregula-
tion of intraepithelial phospho-SMAD2/3 and concomitant
downregulation of phospho-SMAD1/5/8, whereas BMP-7
increased phosphor-SMAD1/5/8 in renal cortical epithelial
cells in vitro [37].
7.4.6. Connective Tissue Growth Factor (CTGF). CTGF is
heparin binding cysteine-rich protein that gets activated
through SMADandMEKpathways; thereby it activates TGF-
𝛽1 and inhibits the antifibrotic effects of BMP-7.The net effect
leads to cellular proliferation, collagen synthesis, chemotaxis,
and EMT [77, 78].
CTGF mRNA and protein levels were increased in a
mouse model of kidney transplantation. In vitro studies
showed CTGF to induce EMT in tubular epithelial cells.
Furthermore, urinary CTGF levels were increased in RT
recipients with chronic allograft fibrosis [79]. In Fisher-to-
Lewis RT model, CTGF silencing with siRNA decreased
allograft fibrosis [80]. No studies on the role of CTGF in
clinical RT have been performed.
7.4.7. SMAD and Rho GTPases Inhibition. TGF-𝛽1 activates
SMAD 2/3 by phosphorylation through the ALK type I
receptor. It can also activate Ras/rho and the downstream
MEK pathway through noncanonical SMAD-independent
pathway [81]. Targeting these downstream molecules in
the TGF-𝛽1 signalling pathway is an alternative antifibrotic
strategy.
In experimental models, inhibition of SMAD3 and rho
prevented fibrogenesis. In unilateral ureteric obstruction
(UUO) model of SMAD3 knockout mice, minimal renal
fibrosis was observed [82]. In the UUO mice model, a rho-
associated coiled-coli forming protein kinase inhibitor (Y-
27632) prevented the transcription of fibrosis genes including
TGF-𝛽1, 𝛼-smooth muscle actin (𝛼-SMA), and 𝛼1-collagen
and matrix deposition [83]. Fasudil, a specific rho kinase
inhibitor, attenuatedmyocardial fibrosis and interstitial fibro-
sis in experimental models of diabetic and obstructive uropa-
thy [84]. However, no preclinical or clinical studies have
examined the role of such intervention in renal allografts.
7.4.8. Vascular Endothelial Growth Factor (VEGF). VEGF is
an antigenic factor expressed in glomerular podocytes and
distal tubules in response to stimuli such as hypoxia, TGF-
𝛽1, epidermal growth factor, and PDGF. VEGF is an inducer
of proliferation (extracellular signal-regulated kinases), per-
meability (endothelial fenestration), invasion (matrix metal-
loproteinases), and survival (activation of Akt/P13K, caspase
inhibition) [85].
One study has examined the influence of VEGF on renal
function and development of interstitial fibrosis in renal
allografts in 92 patients with acute rejection, CAN, and
acute cyclosporine toxicity. Increased VEGF expression was
correlated with increased expression of TNF-𝛼 levels and
macrophage infiltration, associated with increased risk of
early interstitial fibrosis and poor graft outcome in long term
[86].
7.4.9. Hepatocyte Growth Factor (HGF). Hepatocyte growth
factor (HGF) was originally identified and cloned as a potent
mutagen for mature hepatocytes. It is now clear that HGF
acts on various types of cells through its MET receptor tissue
kinase and elicits pleiotropic effects involved in embryogen-
esis and tissue repair [87].
HGF prevents the initiation and progression of renal
fibrosis by inhibiting TGF-𝛽1 expression, myofibroblasts
activation, and EMT. It can block the nuclear transloca-
tion of SMAD-2/3 and upregulate the expression of SMAD
transcriptional compressors, Sloan Kettering Institute (SKI)-
related novel protein N (SnoN), and TG-interacting factors
(TGIF) [88].
In a rat model of CAN, treatment with human recombi-
nant HGF prevented renal allograft inflammation (decreased
TNF-𝛼, MCP-1, and iNOS mRNA levels) and fibrosis
(decreased TGF-𝛽1 mRNA and matrix accumulation) [89].
Similar results were observed following human HGF gene
therapy immediately before and after RT in rats [90]. How-
ever, HGF therapy in RT recipients may be associated with
the potential risk of cancer, given that the HGF receptor
is a tyrosine kinase receptor involved in progression of
carcinomas and metastasis [91].
7.5. Inhibition of Matrix Deposition
7.5.1. Prolyl-4-hydroxylase Inhibitors. In collagen synthesis,
prolyl-4-hydroxylase is essential in posttranslational modifi-
cation of the alpha chains of procollagen. Inhibition of this
enzyme prevents hydroxylation of proline of the procollagen
chain, subsequently causing intracellular degradation of the
procollagen and reduction in the collagen deposition in the
interstitium [92].
Phenanthrolinone, a competitive inhibitor of prolyl-4-
hydroxylase, was studied in a murine model of CAN, which
demonstrated reduction in inflammation and graft fibrosis
along with improvement in graft function.The drug was used
once wounds had healed. Clinical application of this agent
needs to be established [93].
7.5.2. MMP-2, MMP-3, and MMP-9 Inhibitor (Bay 12-9566).
In rat renal allografts, fibrosis is associated with increased
expression of MMP-2 and MMP-9 and decreased tissue
inhibitor of matrix metalloproteinases (TIMP)-3 [94]. BAY
12-9566, an inhibitor of MMP-2, MMP-3, and MMP-9 given
early in the posttransplant period, improved proteinuria and
histology. However, institution at late time-point appeared to
aggravate disease [95].
7.5.3. Retinoids. Retinoids have been recognised for their
anti-inflammatory capacity and their specific receptors are
expressed within the kidney as well as T- and B-cells and
macrophages [96]. Treatment with isotretinoin (13-cisRA)
in a chronic rat allograft model reduced interstitial fibrosis
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and inflammatory cell infiltration and is considered as an
important therapeutic approach when chronic rejection and
immune response are implicated in the allograft injury [97].
7.6. Platelet-DerivedGrowth Factor (PDGF) Inhibitors. PDGF
is a family composed of PDGF-A, PDGF-B, PDGF-C, and
PDGF-D, which are potent growth factors for myofibrob-
lasts, and exerts their cellular effects by binding to tyro-
sine kinase receptors-𝛼 and -𝛽. PDGFs play pivotal roles
in wound healing, regulation of interstitial fluid pressure,
malignancies, atherosclerosis, and fibrotic diseases [98]. The
increased expression of PDGF has been observed in both
animal (mesangioproliferative and rat transplant models)
and human (proliferative GN and diabetic nephropathy,
transplant glomerulopathy) renal diseases [99–102]. PDGF
was present at glomeruli and proximal tubular cells and in
areas of peritubular, interstitial, and periglomerular fibrosis.
In the Dark Agouti to Wistar-Furth rat model of CAN,
imatinib (STI571), a selective PDGF receptor tyrosine kinase
inhibitor, prevented the development of CAN and preserved
renal function [103]. In the same model, similar results
were observed with FK778, a synthetic analogue of an
active metabolite of leflunomide, which inhibited de novo
biosynthesis of pyrimidine and prevented activation of both
T- and B-lymphocytes and expression of TGF-𝛽 ligand and
receptor [104].
7.7. Nuclear Factor Kappa-B (NF-𝜅B) Signalling Inhibitors.
NF-𝜅B comprises a family of transcription factors. NF-𝜅B
pathway is activated by TNF-𝛼, IL-1, and LPS or stress-
mediated cascades. Upon translocation of NF-𝜅B into the
nucleus from cytoplasm, it binds to the DNA and regulates
production of various cytokines, chemokines, stress response
proteins, and antiapoptotic proteins.
Activation of NF-𝜅B is observed in both animal (rat
model of glomerulonephritis) and human (diabetic neph-
ropathy) renal diseases [105, 106]. The NF-𝜅B positive nuclei
were seen in the mesangial cells, endothelial cells, podocytes,
tubular cells, and mononuclear infiltrates in the interstitium.
In both studies, phosphorylation of p38MAP kinase was
observed.
Inhibition of NF-𝜅B using pyrrolidone dithiocarbamate
(PDTC), steroids (prednisolone and dexamethasone), glio-
toxin, parthenolide, and proteasome inhibitor N-benzyloxy-
carbonyl-Ile-Glu (o-t-Bu)-Ala-Leucinal has been examined
in rat models. Significant reduction in inflammation, devel-
opment of fibrosis by reducing MCP-1 gene, and profibrotic
gene expression were observed [107–109].
Activation of NF-𝜅B was inhibited on human proximal
tubular cells when treated with mycophenolic acid [110].
Bortezomib, a proteasome inhibitor, was shown to reduce
antibody production and reduce vasculopathy in rat cardiac
transplantation models [111]. Case reports on the use of
Bortezomib for antibody-mediated rejection are available in
human renal transplantation, but its clinical application is still
in experimental stage [112].
8. Biomarkers of CAN
Several biomarkers of CAN have been examined for early
detection and prediction of CAN, which still remain in
investigative stage. Chemokine (C-Cmotif) ligand 2 (CCL2),
also known as monocyte chemotactic protein-1 (MCP-1),
recruits monocytes, memory T cells, and dendritic cells
to the sites of tissue injury, infections, and inflammation.
Urinary CCL2 was measured and protocol biopsies per-
formed prospectively in 111 RT recipients at 0, 6, and 24
months, which demonstrated urinaryCCL2 at 6months as an
independent risk factor for subsequent development of IFTA
at 24 months, both in univariate and multivariate analyses
[113].
Proteomic analysis of blood samples using mass spec-
trometry has identified several unique signatures of transcript
and protein biomarkers with high predictive accuracies for
mild and moderate/severe CAN, which can be used for
proteogenomic classification of CAN based on peripheral
blood profiling, although the validity remains to be proven
[114, 115].
In 2003, Scherer et al., in their genomics study using
microarray technology, detected upregulation of several
genes, which could predict the development of CAN. Those
genes were APRIL (acidic protein rich in leucines), OBCML
(opiate-binding protein-cell adhesion molecule-like), the
tumour suppressor gene NPRL2, cytokeratin 15, homeobox
gene B7, prolactin receptor, and guanine nucleotide-binding
protein g7 [116]. The same group also demonstrated early
changes in several transcriptomes post-RT, which could
predict development of CAN and identify patients at risk
[117]. More recently, Einecke et al. examined RT biopsy
specimens that showed genes associated with graft failure
were related to tissue injury, epithelial dedifferentiation,
matrix remodelling, and TGF-𝛽. In multivariate analysis,
molecular risk score, peritubular capillary basement mem-
brane multilayering, arteriolar hyalinosis, and proteinuria
were independent predictors of graft loss [118].
Oetting et al. from Minnesota have investigated the
effect of telomere length (TL) on the allograft survival and
CAN by measuring TL in DNA isolated from peripheral
blood in 1805 recipients and 1038 living kidney donors
using the multiplexed monochrome quantitative polymerase
chain reaction assay. They concluded that the CAN was not
associated with shorter TL, although older donor chrono-
logical age was associated with increased risk of CAN [119].
Molecular profiling is a newer advancement in identifying
molecular signatures related to CAN. Maluf et al. have
identified calcineurin inhibitor toxicity at the molecular level
as a nonimmunological factor involved in the progression to
CAD [120].
9. Conclusions
CAN, once established, is irreversible [3, 23]. Delaying the
progression of renal fibrosis and preservation of allograft
function should be the goal, which is being achieved through
substitutionwith less nephrotoxic immunosuppressive agents
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and modification of risk factors, such as adequate con-
trol of hypertension, diabetes, hyperlipidaemia, proteinuria
(angiotensin blockade), and infections (CMV, BKV, and urine
tract infections). CNI minimisation and steroid-sparing reg-
imens were shown to reduce the progression of CAN [121,
122]. Substitution of CNIs with sirolimus and mycophenolate
mofetil leads to improvement and preservation of renal
function in CAN cases [123, 124]. Early diagnosis of CAN
through protocol biopsies and institution of appropriate
immunosuppressive regimens and treatment of subclinical
rejection is essential to prevent late diagnosis of CAN [125].
Several interventional strategies have been examined to
block the intracellular and extracellular cascades of events at
molecular levels in both clinical and experimental settings
to prevent CAN, but limited success has been achieved
[33, 49]. Preventive and treatment strategies targeting TGF-
𝛽1 signalling pathway are reasonable antifibrotic options in
RT, but TGF-𝛽 expression in RT is being considered to be
beneficial because of its effect in gaining tolerance [33]. More
specifically, PFD and therapies targeting BMP-7, HGF, and
CTGF, although having shown promising results, still are
in the experimental phase [76]. Exploration of alternative
pathways and downstream molecules is critical for develop-
ing new strategies to ameliorate graft fibrosis and atrophy.
Clinical trials are needed to examine their long-term effects in
RT. Modulation of the risk factors, both immunological and
nonimmunological, have been successful in slowing down
the progression of CAN to some extent, but not successful in
prevention or reversal of the ultimate changes of CAN [126–
128].
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